I D Glick

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi Managing psychiatric issues in elite athletes
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA
    J Clin Psychiatry 73:640-4. 2012
  2. ncbi Understanding the results of CATIE in the context of the field
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    CNS Spectr 11:40-7. 2006
  3. ncbi Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Int Clin Psychopharmacol 21:261-6. 2006
  4. ncbi Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Psychiatry 67:1261-5. 2006
  5. ncbi Through the golden chalkboard: twelve teaching pearls on the teaching-learning process in psychiatry
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Acad Psychiatry 30:422-3. 2006
  6. ncbi The ACNP and me
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
    Acad Psychiatry 31:125-6. 2007
  7. ncbi Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients
    Ira D Glick
    Stanford University School of Medicine, Department of Psychiatry, 401 Quarry Rd, Suite 2122, Stanford, CA 94305, USA
    J Clin Psychiatry 69:1856-9. 2008
  8. ncbi Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA
    J Clin Psychiatry 72:1616-27. 2011
  9. ncbi The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, and Psychopharmacology, Stanford University School of Medicine, Stanford, CA, USA
    J Affect Disord 115:18-26. 2009
  10. ncbi A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive
    Ira D Glick
    Department of Psychiatry, Schizophrenia Clinic, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Psychopharmacol 29:267-71. 2009

Detail Information

Publications43

  1. ncbi Managing psychiatric issues in elite athletes
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA
    J Clin Psychiatry 73:640-4. 2012
    ..These patients present with multifaceted medical, psychological, and performance concerns. We provide the first report of professional and ethical quandaries that arise in treating elite athletes and ways to address them...
  2. ncbi Understanding the results of CATIE in the context of the field
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    CNS Spectr 11:40-7. 2006
    ..What should emerge from CATIE is a renewed commitment to tailor schizophrenia treatment to the individual patient for long-term management...
  3. ncbi Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Int Clin Psychopharmacol 21:261-6. 2006
    ..1-1.5). These findings are clinically relevant because the faster onset of therapeutic effect with atypical antipsychotics can be important in the acute setting and have a considerable impact on healthcare systems...
  4. ncbi Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Psychiatry 67:1261-5. 2006
    ..To our knowledge, there have been no published reports of prospective systematic investigations of the efficacy of unrestricted CPM use in nonacute schizophrenia...
  5. ncbi Through the golden chalkboard: twelve teaching pearls on the teaching-learning process in psychiatry
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Acad Psychiatry 30:422-3. 2006
  6. ncbi The ACNP and me
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
    Acad Psychiatry 31:125-6. 2007
  7. ncbi Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients
    Ira D Glick
    Stanford University School of Medicine, Department of Psychiatry, 401 Quarry Rd, Suite 2122, Stanford, CA 94305, USA
    J Clin Psychiatry 69:1856-9. 2008
    ..This study examined aripiprazole treatment of patients with comorbid schizophrenia and obsessive-compulsive symptoms (OCS) that did not meet full criteria for OCD...
  8. ncbi Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA
    J Clin Psychiatry 72:1616-27. 2011
    ....
  9. ncbi The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, and Psychopharmacology, Stanford University School of Medicine, Stanford, CA, USA
    J Affect Disord 115:18-26. 2009
    ..Because efficacy may be better in schizoaffective disorder than schizophrenia, this post-hoc analysis examines the efficacy, safety, and tolerability of aripiprazole in patients with schizoaffective disorder...
  10. ncbi A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive
    Ira D Glick
    Department of Psychiatry, Schizophrenia Clinic, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Psychopharmacol 29:267-71. 2009
    ..To compare the efficacy of mood stabilizer augmentation of an antipsychotic for patients with schizophrenia who are both stabilized and partially responsive...
  11. ncbi The evolution of sport psychiatry, circa 2009
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA
    Sports Med 39:607-13. 2009
    ..Case examples, a training curriculum and core literature are included...
  12. ncbi Onset and persistence of antipsychotic response in patients with schizophrenia
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Suite 2122, 401 Quarry Rd, Stanford, CA 94305, USA
    J Clin Psychopharmacol 29:542-7. 2009
    ..Results suggest that persistent response requires continuing antipsychotic treatment beyond 2 weeks in some patients. These results may be useful for clinical decision making and patient education...
  13. ncbi Psychiatric conditions in sports: diagnosis, treatment, and quality of life
    Ira D Glick
    Stanford University School of Medicine, 401 Quarry Road, Suite 2122, Stanford, CA 94305, USA
    Phys Sportsmed 37:29-34. 2009
    ..Confidentiality issues are paramount during diagnosis and treatment. Physicians who understand sports and team dynamics may have more success in helping patients follow through with treatment...
  14. ncbi Psychiatric conditions in sports: diagnosis, treatment, and quality of life
    I D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305 5723, USA
    Phys Sportsmed 29:44-55. 2001
    ..Confidentiality issues are paramount during diagnosis and treatment. Physicians who understand sports and team dynamics may have more success in helping patients follow through with treatment...
  15. ncbi Improving the pedagogy associated with the teaching of psychopharmacology
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Acad Psychiatry 31:211-7. 2007
    ..The focus was on whether "improving the teaching-learning process" in psychiatric residency programs could improve clinical practice...
  16. ncbi Treatment with atypical antipsychotics: new indications and new populations
    I D Glick
    Professor of Psychiatry, Stanford University School of Medicine, 401 Quarry Road, Suite No 2122, Stanford, CA 94305, USA
    J Psychiatr Res 35:187-91. 2001
    ....
  17. ncbi Diagnosis and psychiatric treatment of athletes
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5723, USA
    Clin Sports Med 24:771-81, vii. 2005
    ..A special concern is minimizing countertransference feelings and avoiding undertreatment, because by definition the athlete needs to perform...
  18. ncbi The challenge of teaching psychopharmacology in the new millennium: the role of curricula
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine, Stanford, California, USA
    Acad Psychiatry 29:134-40. 2005
    ....
  19. ncbi Adding psychotherapy to pharmacotherapy: data, benefits, and guidelines for integration
    Ira D Glick
    Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, 401 Quarry Rd, 2122, Stanford, California 94305-5546, USA
    Am J Psychother 58:186-208. 2004
  20. ncbi Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 101 Quarry Road 2122, Stanford, CA 94305, USA
    J Clin Psychiatry 66:638-41. 2005
    ..To compare the long-term efficacy and tolerability of oral quetiapine with those of intramuscular haloperidol...
  21. ncbi Teaching pearls from the lost art of psychopharmacology
    Ira D Glick
    Stanford University School of Medicine, USA
    J Psychiatr Pract 15:423-6. 2009
    ..In this article, the authors present their collection of psychopharmacology "pearls" for trainees as well as experienced clinicians. (Journal of Psychiatric Practice 2009;15:423-426)...
  22. ncbi Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia
    I D Glick
    Stanford University School of Medicine, California 94305 5723, USA
    Ann Intern Med 134:47-60. 2001
    ..Some of the new directions in dinical research to refine these strategies and meet these challenges are also described...
  23. ncbi Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders
    I D Glick
    Stanford University School of Medicine, Department of Psychiatry, CA 94305, USA
    Int Clin Psychopharmacol 17:65-8. 2002
    ....
  24. ncbi The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies
    Philip G Janicak
    Department of Psychiatry, Rush University Medical Center, Chicago, Illinoise 60612, USA
    J Clin Psychiatry 70:25-35. 2009
    ..To evaluate the efficacy of aripiprazole across a range of symptoms-positive, negative, disorganized thought, depression/anxiety, and hostility-in schizophrenia and schizoaffective disorder...
  25. ncbi Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior
    Ira D Glick
    Stanford University School of Medicine, Stanford, California, USA
    J Clin Psychiatry 65:679-85. 2004
    ..CONCLUSION: The results support the conclusion that the effects of clozapine in reducing the risk of suicidal behavior derive from its intrinsic pharmacology and not from the influence of concomitant psychotropic medications...
  26. ncbi Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents
    I D Glick
    Stanford University School of Medicine, CA, USA
    Int Clin Psychopharmacol 16:265-74. 2001
    ..8%, 33.7% and 34.4% of patients, respectively. These findings are consistent with earlier findings that show risperidone is more efficacious than haloperidol for reducing the symptoms of schizophrenia...
  27. ncbi Olanzapine and haloperidol in first episode psychosis: two-year data
    A I Green
    Department of Psychiatry, Dartmouth Medical School, DHMC, Lebanon, NH 03756, USA
    Schizophr Res 86:234-43. 2006
    ..The data from this study suggest some clinical benefits for olanzapine as compared to haloperidol in first episode patients, which must be weighed against those adverse effects that are more likely with olanzapine...
  28. ncbi Divalproex for the treatment of geriatric bipolar disorder
    D J Mordecai
    Stanford University School of Medicine, Stanford, California 94305, USA
    Int J Geriatr Psychiatry 14:494-6. 1999
    ..Of the six, five showed some improvement with divalproex alone or in combination with other agents. Clearly, a double-blind, placebo-controlled study is an important next step to assess this promising medication...
  29. ncbi Teaching psychopharmacology: what works and what doesn't
    Sidney Zisook
    Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA
    J Clin Psychopharmacol 28:96-100. 2008
    ....
  30. ncbi Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study
    Sun H Kim
    Division of Endocrinology, Stanford University, Stanford, CA, USA
    J Clin Psychopharmacol 27:365-8. 2007
    ..In conclusion, switching to aripiprazole alone does not ameliorate the highly prevalent metabolic abnormalities in the schizophrenia population who have gained weight on other second generation antipsychotic medications...
  31. ncbi Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial
    Miranda H Chakos
    Department of Psychiatry, State University of New York Downstate Medical Center, Brooklyn, 11572, USA
    Psychiatr Serv 57:1094-101. 2006
    ..CONCLUSIONS: Concomitant use of psychotropic medications to treat people with schizophrenia is common. Empirical data demonstrating the effectiveness of many of these agents for this population are lacking...
  32. ncbi Clinical trials design lessons from the CATIE study
    Helena Chmura Kraemer
    Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA 94301, USA
    Am J Psychiatry 166:1222-8. 2009
    ....
  33. ncbi Combining pharmacotherapy with psychotherapeutic management: guidelines for integration
    Ira D Glick
    Stanford University School of Medicine, CA, USA
    J Clin Psychiatry 67:1645-6. 2006
  34. ncbi The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development
    T Scott Stroup
    Department of Psychiatry, University of North Carolina School of Medicine, Neurosciences Hospital, Chapel Hill 27599 7160, USA
    Schizophr Bull 29:15-31. 2003
    ..If the phase 2 study drug is discontinued, subjects may enter phase 3, in which clinicians help subjects select an open-label treatment based on individuals' experiences in phases 1 and 2...
  35. ncbi Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect
    John M Davis
    Department of Psychiatry, University of Illinois at Chicago, 1601 W Taylor Street, Chicago, IL 60612, USA
    Neuropsychopharmacology 33:971-5. 2008
    ..We were unable to confirm that the drug's EPS properties or antiparkinsonian management altered actual efficacy...
  36. ncbi Psychiatric conditions in cosmetic surgery patients
    Eva C Ritvo
    Department of Psychiatry and Behavioral Sciences, University of Miami, Miller School of Medicine, Miami, Florida 33101, USA
    Facial Plast Surg 22:194-7. 2006
    ....
  37. ncbi Insight in first-episode psychosis
    Joseph P McEvoy
    John Umstead Hospital, Duke University Department of Psychiatry, Butner, NC 27509, USA
    Psychol Med 36:1385-93. 2006
    ....
  38. ncbi A meta-analysis of the efficacy of second-generation antipsychotics
    John M Davis
    Psychiatric Institute, University of Illinois at Chicago, 60612, USA
    Arch Gen Psychiatry 60:553-64. 2003
    ....
  39. ncbi Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder
    George M Simpson
    Department of Psychiatry and the Behavioral Sciences, LAC USC Medical Center, IRD RM 204, Psychiatric Outpatient Clinic, 2020 Zonal Ave, Los Angeles, CA 90033, USA
    Am J Psychiatry 161:1837-47. 2004
    ..The authors compared the efficacy and tolerability of ziprasidone and olanzapine in the treatment of acutely ill inpatients with schizophrenia or schizoaffective disorder...
  40. ncbi Drug and psychosocial curricula for psychiatry residents for treatment of schizophrenia: part I
    Robert Paul Liberman
    Neuropsychiatric Institute, University of California-Los Angeles, 760 Westwood Plaza, Los Angeles, CA 90095, USA
    Psychiatr Serv 55:1217-9. 2004
  41. ncbi The challenge of teaching psychopharmacology and improving clinical practice
    Ira D Glick
    J Clin Psychopharmacol 25:203-5. 2005
  42. ncbi Aripiprazole as a dopamine partial agonist: positive and negative effects
    Ira D Glick
    J Clin Psychopharmacol 26:101-3. 2006
  43. ncbi Treating schizophrenia with comorbid depressive or demoralization symptoms
    Ira D Glick
    J Clin Psychiatry 69:501. 2008